Showing 28 articles by Andy Carstens

Filters Content type: News, About HIV Author: Andy Carstens

Andy is a freelance science journalist based in Denver in the United States with a master’s in science writing from Johns Hopkins University. In addition to his work at aidsmap.com, Andy’s writing has appeared at The Scientist, Audubon, Slate, and Them. Andy first joined our Emerging Voices programme in  2021. Twitter: @Andy_Carstens

PrEP science

Enemas, suppositories, and inserts are acceptable for applying HIV-prevention medicine before anal sex

News
23 June 2023
PrEP science

PrEP failures (breakthrough infections)

About HIV
June 2023
Neurological & cognitive problems

People with HIV, especially women, may have a higher prevalence of dementia as they age

News
8 June 2023
Starting treatment

People with weakened immune systems still at risk of treatment failure, even with newer ART regimens

News
31 May 2023
How HIV works

HIV controllers may be more susceptible to non-AIDS illnesses compared to people on HIV treatment

News
9 May 2023
Transgender people

Two studies give much needed (but still insufficient) insights into transgender men’s sexual health needs

News
24 April 2023
The search for a cure

Gene therapy decreases HIV reservoir and moderately suppresses viral load in some

News
4 April 2023
Mpox (monkeypox)

First, second, and third generation smallpox vaccines all protect against mpox infection

News
23 February 2023
The search for an HIV prevention vaccine

Mosaico trial closure shifts vaccine focus to neutralising antibodies

News
22 February 2023
Sexually transmitted infections prevention

Prescribing doxyPEP after STI diagnosis is more efficient than targeting specific groups of people

News
22 February 2023
How HIV works

HIV reservoir cells have surface proteins that aid in evading immune attack

News
20 January 2023
How HIV works

HIV-specific immune response unconnected to inflammation in people taking ART

News
17 January 2023
Antibody-based treatment

Do broadly neutralising antibodies really have a future in treating HIV?

News
11 November 2022
PrEP

Truvada or Descovy: which should I take for PrEP?

About HIV
May 2022
Antibody-based treatment

Repeated infusions of two antibodies delay viral rebound but don’t prevent it

News
13 May 2022
Access to healthcare

The COVID-19 pandemic disrupted HIV prevention and care in Barcelona, but new cases and viral loads didn’t increase

News
28 April 2022
Clinical trials

Can HIV cure trials strike a balance between the need for meaningful data and participant safety?

News
18 April 2022
Kidney problems

PrEP and kidney function: who really needs screening and can event-based dosing reduce side-effects?

News
1 April 2022
Mental & emotional health & wellbeing

PrEP increases sexual pleasure, intimacy, and closeness

News
11 March 2022
Ethnic & cultural minorities

Higher risks of cancer for Black men with HIV suggest racial inequities in US health care

News
8 March 2022
People who inject drugs

Tele-harm reduction: a new approach in the US shows promise for people with HIV who inject drugs

News
2 February 2022
Coronavirus

Further evidence that COVID breakthrough infections are more common in people living with HIV

News
20 January 2022
Mental & emotional health problems

Integrating lay counsellors into routine HIV care improved mental health symptoms in Mozambique

News
19 January 2022
Treatment simplification strategies

History of drug resistance or virological failure warrants caution when switching to dolutegravir plus lamivudine

News
30 December 2021